Hoth Therapeutics 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가	US$0.60
52주 최고가	US$2.12
52주 최저가	US$0.49
베타	0.58
1개월 변동	-19.36%
3개월 변동	-43.93%
1년 변동	-28.16%
3년 변동	-62.51%
5년 변동	-98.31%
IPO 이후 변동	-99.72%

최근 뉴스 및 업데이트

Recent updates

분석 기사 • Sep 08

Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation

Hoth Therapeutics (NASDAQ: HOTH) is emerging as one of the most intriguing small-cap biotech stories on the market. With a market capitalization of just ~$16 million, the company is combining tangible clinical success with cutting-edge AI tools, creating a potentially asymmetric investment opportunity.

분석 기사 • Sep 05

Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks

This week’s picks cover: Why Venmo and merchant solutions are driving PayPal’s upside potential, how IREN’s pivot from Bitcoin mining to AI infrastructure is adding value, and how Cadeler’s fleet expansion rides offshore wind growth.

내러티브 업데이트 • Sep 05

100% Patient Improvement in trial puts this $16M Biotech on the radar

Strengthening Pipeline with Breakthrough AI Hoth Therapeutics (NASDAQ: HOTH) is layering cutting-edge technology on top of its strong clinical momentum. Already known for its standout Phase 2 trial results (100% patient improvement with HT-001 cancer rash trial), Hoth is now integrating Lantern Pharma’s PredictBBB.ai platform , an AI tool with 94% accuracy in predicting whether drugs can cross the blood–brain barrier (BBB).

새로운 내러티브 • Sep 01

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.

Seeking Alpha • Sep 20

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Hoth Therapeutics (NASDAQ:HOTH) said on Tuesday it had signed an agreement with Altasciences to develop and manufacture the HT-TBI drug product formulation for the treatment and/or prevention of secondary brain injury. HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel. "We are leveraging Altasciences' expertise to develop and manufacture novel parenteral formulations to achieve a formulation that requires no preparation or special storage requirements to ensure HT-TBI can be used anywhere in the field at the time a head injury or stroke occurs," the company said.

Seeking Alpha • Jun 29

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Nasdaq has granted Hoth Therapeutics (NASDAQ:HOTH) an additional 180-days or until December 26, 2022 to regain compliance with minimum $1.00 closing bid price per share requirement. In a letter dated December 30, 2021, the company was notified that the minimum bid price per share for its common shares has been below $1.00 for a period of 30 consecutive business days and it no longer meets the minimum bid price requirements. The company having provided written notice of its intention to cure the deficiency during the Additional Compliance Period, including by effecting a reverse stock split, if necessary. If the company does not comply with the minimum bid price requirement during the 180-day grace period than its shares are subject to delisting. Shares plunged around 72% over a period of one year.

주주 수익률

	HOTH	US Pharmaceuticals	US 시장
7D	-8.6%	1.8%	-1.0%
1Y	-28.2%	36.1%	23.3%

수익률 대 산업: HOTH은 지난 1년 동안 36.1%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.

수익률 대 시장: HOTH은 지난 1년 동안 23.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.

주가 변동성

Is HOTH's price volatile compared to industry and market?
HOTH volatility
HOTH Average Weekly Movement	15.3%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.2%

안정적인 주가: HOTH의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.

시간에 따른 변동성: HOTH의 주간 변동성(15%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.

회사 소개

설립	직원 수	CEO	웹사이트
2017	3	Robb Knie	hoththerapeutics.com

임상 단계의 바이오 제약 회사인 Hoth Therapeutics는 미국의 미충족 의료 수요에 대한 치료법 개발에 주력하고 있습니다. 회사는 티로신 키나제 표피 성장 인자 수용체 억제제 치료의 초기 및 반복 과정과 관련된 발진 및 피부 질환 환자 치료를 위한 임상 2상 시험 중인 국소 제형 HT-001, 비만 세포 유래 암 및 아나필락시스 치료를 위한 HT-KIT, 외상성 뇌 손상 및 허혈성 뇌졸중 치료를 위한 HT-TBI, 알츠하이머 또는 기타 신경염증 질환의 치료 및 예방을 위한 HT-ALZ, 흡입 투여로 천식과 알레르기 치료를 위한 HT-004를 개발 중입니다. 또한 습진 치료를 위한 임상 1상 시험 중인 특허받은 독점적 약물 화합물 플랫폼인 BioLexa 플랫폼과 루푸스 환자 치료를 위한 HT-005를 개발하고 있습니다.

Hoth Therapeutics, Inc. 기초 지표 요약

Hoth Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
HOTH 기초 통계
시가총액	US$11.48m
순이익 (TTM)	-US$11.69m
매출 (TTM)	n/a

0.0x

주가매출비율(P/S)

-1.0x

주가수익비율(P/E)

HOTH는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
HOTH 손익계산서 (TTM)
매출	US$0
매출원가	US$0
총이익	US$0
기타 비용	US$11.69m
순이익	-US$11.69m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

해당 없음

주당순이익(EPS)	-0.61
총이익률	0.00%
순이익률	0.00%
부채/자본 비율	0%

HOTH의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/20 01:04
종가	2026/05/20 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Hoth Therapeutics, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jason Kolbert	D. Boral Capital LLC.

Hoth Therapeutics (HOTH) 주식 개요

위험 분석

Top Community Narratives

100% Patient Improvement in trial puts this $16M Biotech on the radar

Top Community Narratives

100% Patient Improvement in trial puts this $16M Biotech on the radar

Hoth Therapeutics, Inc. 경쟁사

Rize Oncology

Kiora Pharmaceuticals

Vyome Holdings

Akanda

가격 이력 및 성과

최근 뉴스 및 업데이트

Hoth Therapeutics, Inc. Secures European Authorization In Spain For HT-001 Phase 2a Trial As Interim Data Show Strong Efficacy In Cancer Patients

Hoth Therapeutics, Inc. Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

Hoth Therapeutics Reports Positive Data for GDNF in Liver Fat Metabolism and Outperforms Semaglutide

New major risk - Shareholder dilution

Hoth Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

New minor risk - Share price stability

Recent updates

Hoth Therapeutics, Inc. Secures European Authorization In Spain For HT-001 Phase 2a Trial As Interim Data Show Strong Efficacy In Cancer Patients

Hoth Therapeutics, Inc. Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

Hoth Therapeutics Reports Positive Data for GDNF in Liver Fat Metabolism and Outperforms Semaglutide

New major risk - Shareholder dilution

Hoth Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

New minor risk - Share price stability

Hoth Therapeutics Announces Positive Clinical Results for HT-001 Program

Hoth Therapeutics Inc Deploys OpenClaw AI Platform to Accelerate Drug Discovery

Hoth Therapeutics Reports Positive HT-001 Pharmacokinetic, Safety, and Clinical Activity Data in Cancer Patients with EFGR Therapy-Associated Skin Toxicities

Hoth Therapeutics Reports Positive Female Preclinical Data Showing Ht-Va Restores Cholesterol Levels and Improves Lipid Metabolism in Masld Model

Hoth Therapeutics, Inc. Announces Significant Expansion of Its Cleer-001 Phase 2A Clinical Trial with the Addition of Regis Clinical Research as A New Enrolling Site

Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's Ht-Va Gdnf Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Hoth Therapeutics, Inc. Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated Ht-Kit, Advancing Ht-001 Phase 2, and New Gdnf Metabolic Program

New major risk - Financial position

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rarec-KIT-Driven Cancers

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Hoth Therapeutics, Inc. Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and Menin Inhibitor-Associated Skin Toxicities

Hoth Therapeutics, Inc. Announces Expansion of Phase II Clinical Trial Infrastructure

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation

Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks

100% Patient Improvement in trial puts this $16M Biotech on the radar

Hoth Therapeutics Inc.'s Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones with Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

100% Patient Improvement in trial puts this $16M Biotech on the radar

Hoth Therapeutics HT-001 Interim Results First-In-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway

Hoth Therapeutics, Inc., Annual General Meeting, Aug 05, 2025

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Receives Notice of Delisting Due to Non-Compliance with Nasdaq Bid Price

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive Kit-Driven Cancers

Hoth Therapeutics Receives Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Hoth Therapeutics, Inc. Announces Board and Committee Changes, Effective as of April 15, 2025

Hoth Therapeutics Announces Positive Initial Data in Phase 2A Clinical Trial

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease

New major risk - Financial position

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for Ht-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Regains Compliance with Nasdaq Listing Rules

Hoth Therapeutics, Inc. Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.7 million.

Hoth Therapeutics Notifies by the Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirements

Hoth Therapeutics, Inc. Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics, Inc. Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

New major risk - Share price stability

Price target decreased by 14% to US$4.50

New minor risk - Share price stability

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics, Inc. Expands Clinical Trial for Cancer Patients

New major risk - Shareholder dilution

Hoth Therapeutics, Inc., Annual General Meeting, Aug 07, 2024

New major risk - Financial position

Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients